| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 07/24/2003 | US20030139368 Antithrombotic and/or anti-inflammatory composition combining purine activity and NSAID activity |
| 07/24/2003 | US20030139353 Using topoisomerase inhibitor; antiarthritic agents; respiratory system disorders; skin disorders |
| 07/24/2003 | US20030139350 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 07/24/2003 | US20030139340 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI) |
| 07/24/2003 | US20030139339 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor ( TFPI) |
| 07/24/2003 | US20030138926 Novel polynucleotides and polypeptides encoded thereby |
| 07/24/2003 | US20030138841 Library of novel ''unnatural'' natural products |
| 07/24/2003 | US20030138815 Cyclic adenosine monophosphate (cAMP); drug screening; bronchodilators; antiinflammatory agents; immunomodulators; antiallergens; bioassays |
| 07/24/2003 | US20030138772 Polymerase chain reactions to screen and isolate parvovirus DNA obtained from tissue and/or cells without coinfection by helper viruses; gene therapy |
| 07/24/2003 | US20030138503 Topical pharmaceutical formulations and methods of treatment |
| 07/24/2003 | US20030138467 Methods for improving the aesthetic appearance of skin |
| 07/24/2003 | US20030138440 Multimeric proteins and methods of making and using same |
| 07/24/2003 | US20030138423 Antiinflammation agents and immunotherapy using an enzyme inhibitor; sepsis; antiarthritic and - ulcer agents; colitis; myocarditis; glomerulonephritis; gastrointestinal and nervous system disorders; Crohn's disease; automimmune |
| 07/24/2003 | US20030138421 Human Antibodies specific for interleukin 15 (IL-15) |
| 07/24/2003 | US20030138407 Therapeutic methods for nucleic acid delivery vehicles |
| 07/24/2003 | CA2474239A1 Substituted pyridazinones as inhibitors of p38 |
| 07/24/2003 | CA2474141A1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 07/24/2003 | CA2473893A1 Stable salts of o-acetylsalicylic acid with basic amino acids ii |
| 07/24/2003 | CA2472746A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| 07/24/2003 | CA2472459A1 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections |
| 07/24/2003 | CA2472204A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/24/2003 | CA2472168A1 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/24/2003 | CA2471702A1 Human monoclonal antibodies against cd30 |
| 07/24/2003 | CA2471562A1 Tyrosyl derivatives and their use as p2x7 receptor modulators |
| 07/24/2003 | CA2471513A1 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2470649A1 Mmp inhibitors |
| 07/24/2003 | CA2469800A1 Methods for the induction of professional and cytokine-producing regulatory cells |
| 07/24/2003 | CA2469435A1 Modulators of lxr |
| 07/24/2003 | CA2468610A1 Method for reducing morbidity and mortality in critically ill patients |
| 07/23/2003 | EP1329451A1 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 07/23/2003 | EP1329223A1 Expression potentiator for protein synthesis regulatory gene |
| 07/23/2003 | EP1329222A1 Isoflavone compositions for use in medicine |
| 07/23/2003 | EP1328807A2 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 07/23/2003 | EP1328629A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 07/23/2003 | EP1328624A2 B7-like molecules and uses thereof |
| 07/23/2003 | EP1328619A1 Human tuberoinfundibular peptide of 39 residues |
| 07/23/2003 | EP1328548A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 07/23/2003 | EP1328539A1 Vegf peptides and their use for inhibiting angiogenesis |
| 07/23/2003 | EP1328519A2 Orally active salts with tyrosine kinase activity |
| 07/23/2003 | EP1328516A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds |
| 07/23/2003 | EP1328514A1 Amide derivatives as nmda receptor antagonists |
| 07/23/2003 | EP1328507A1 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents |
| 07/23/2003 | EP1328319A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 07/23/2003 | EP1328289A2 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof |
| 07/23/2003 | EP1328272A1 Nf-kappa-b inhibitors |
| 07/23/2003 | EP1328271A2 Method for the treatment of neurological and neuropsychological disorders |
| 07/23/2003 | EP1328270A2 Method for the treatment of neurological and neuropsychological disorders |
| 07/23/2003 | EP1328267A2 Method of treating cancer using dithiocarbamate derivatives |
| 07/23/2003 | EP1328265A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions |
| 07/23/2003 | EP1328260A2 Methods and products related to pulmonary delivery of polysaccharides |
| 07/23/2003 | EP1328254A2 Lipid formulations for target delivery |
| 07/23/2003 | EP1328252A2 Transdermal pharmaceutical delivery composition |
| 07/23/2003 | EP1328245A1 Dental care compositions |
| 07/23/2003 | EP1328236A2 Methods of decreasing or preventing pain using spicamycin derivatives |
| 07/23/2003 | EP1254134B1 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors |
| 07/23/2003 | EP1228073B1 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 07/23/2003 | EP1155013B1 Heterocyclic benzenesulphonamide compounds as bradykinine antagonists |
| 07/23/2003 | EP1148876A4 Calcilytic compounds |
| 07/23/2003 | EP1107741B1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 07/23/2003 | EP1089753B1 Use of a dipeptide for stimulating repair processes |
| 07/23/2003 | EP1086096B1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| 07/23/2003 | EP1069913B1 Gelling ophthalmic compositions containing xanthan gum |
| 07/23/2003 | EP1032575B1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 07/23/2003 | EP1019078B1 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis |
| 07/23/2003 | EP0898559B1 Cytoprotective compounds |
| 07/23/2003 | EP0714408B1 Tryptase inhibitor |
| 07/23/2003 | CN1432020A 嘌呤衍生物 Purine derivatives |
| 07/23/2003 | CN1432018A Crystalline and amorphous form of triazolo (4,5-d) pyrimidine compound |
| 07/23/2003 | CN1432015A Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |
| 07/23/2003 | CN1432013A Imidazole derivatives or salts thereof and drugs contg. derivatives or salts |
| 07/23/2003 | CN1432012A Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for treatment of pain |
| 07/23/2003 | CN1432011A Benzoamide piperidine compounds as substance P antagonists |
| 07/23/2003 | CN1432007A Inhibitors of alpha L beta 2 mediated cell adhesion |
| 07/23/2003 | CN1432000A TNF-alpha prodn. inhibitors |
| 07/23/2003 | CN1431999A Indole derivatives with vascular damagine activity |
| 07/23/2003 | CN1431941A 挤压模 Extrusion die |
| 07/23/2003 | CN1431908A Kits and methods for optimizing efficacy of chondroprotective compsns. |
| 07/23/2003 | CN1431904A Protease inhitors |
| 07/23/2003 | CN1431902A Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 07/23/2003 | CN1431899A Pharmaceutical combination of bicalutamide and tamoxifen for providing anti-androgenic effect and anti-oestrogenic effect |
| 07/23/2003 | CN1431012A Externally used Chinese herbal medicine for treating gynecology inflammation |
| 07/23/2003 | CN1431009A Medicine for curing wind dampness, injuries from falls and ulcer in opening of sore |
| 07/23/2003 | CN1431003A Medicine for curing cerebral concussion and injuries from falls |
| 07/23/2003 | CN1430987A Chewing tablet of hydrochloric bastardtoad flax and creation technique |
| 07/23/2003 | CN1115165C Externally applied medicated wine for treating traumatic injury and rheumatism |
| 07/23/2003 | CN1115161C Aitonging plaster for treating cancer and its prepn. method |
| 07/22/2003 | US6596900 Brain, nervous system, neurodegenerative, gastrointestinal, sleep, rheumatic, and psychological disorders; analgesics, antiepileptic agents |
| 07/22/2003 | US6596851 Antibody for use in the treatment of cell proliferative disorders |
| 07/22/2003 | US6596773 Central nervous system disorders |
| 07/22/2003 | US6596764 Method of preparing diacetyl rhein |
| 07/22/2003 | US6596761 Cosmetic and dermatological preparation with flavonoids |
| 07/22/2003 | US6596751 α-substituted carboxylic acid derivatives |
| 07/22/2003 | US6596746 Cyclic protein tyrosine kinase inhibitors |
| 07/22/2003 | US6596745 Method for treating fibrotic diseases with azolium chroman compounds |
| 07/22/2003 | US6596738 Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): |
| 07/22/2003 | US6596726 Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme |
| 07/22/2003 | US6596721 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 07/22/2003 | US6596715 Protease inhibitors |
| 07/22/2003 | US6596701 S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |